Vincenzi M, Kremic A, Jouve A, Lattanzi R, Miele R, Benharouga M, Alfaidy-Benharouga N, Migrenne-Li S, Kanthasamy AG, Porcionatto M, Ferrara N, Tetko IV, Désaubry L, Nebigil CG

Pharmacol Rev. 2023 09 8;:

Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.

Najem A, Krayem M, Sabbah S, Pesetti M, Journe F, Awada A, Désaubry L, Ghanem GE

Cells. 2023 07 14;12(14):

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo.

Liu J, Zhang R, Su T, Zhou Q, Gao L, He Z, Wang X, Zhao J, Xing Y, Sun F, Cai W, Wang X, Han J, Qin R, Désaubry L, Han B, Chen W

J Exp Clin Cancer Res. 2023 05 20;42(1):128

The flavagline FL3 interferes with the association of Annexin A2 with the eIF4F initiation complex and transiently stimulates the translation of A2 mRNA.

Grindheim AK, Patil SS, Nebigil CG, Désaubry L, Vedeler A

Front Cell Dev Biol. 2023 05 12;11:1094941

Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as therapeutic strategy in CLL.

Largeot A, Klapp V, Viry E, Gonder S, Fernandez Botana I, Blomme A, Benzarti M, Pierson S, Duculty C, Marttila P, Wierz M, Gargiulo E, Pagano G, An N, El Hachem N, Perez Hermandez D, Chakraborty S, Ysebaert L, François JH, Cortez Clemente SD, Berchem G, Efremov DG, Dittmar G, Szpakowska M, Chevigne A, Nazarov PV, Helleday T, Close P, Meiser J, Stamatopoulos B, Désaubry L, Paggetti J, Moussay E

Blood. 2023 04 21;:

eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma.

Steinmann SM, Sánchez-Martín A, Tanzer E, Cigliano A, Pes GM, Simile MM, Desaubry L, Marin JJG, Evert M, Calvisi DF

Int J Mol Sci. 2023 01 20;24(3):

Triazine-Based Small Molecules: A Potential New Class of Compounds in the Antifungal Toolbox.

Conrad KA, Kim H, Qasim M, Djehal A, Hernday AD, Désaubry L, Rauceo JM

Pathogens. 2023 01 12;12(1):

Non-classical ferroptosis inhibition by a small molecule targeting PHB2.

Yang W, Mu B, You J, Tian C, Bin H, Xu Z, Zhang L, Ma R, Wu M, Zhang G, Huang C, Li L, Shao Z, Dai L, Désaubry L, Yang S

Nat Commun. 2022 12 3;13(1):7473

Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis.

Chouha N, Abou-Hamdan H, Yurugi H, Yoshii R, Ii H, Najem A, Ghanem GE, Nakata S, Rajalingam K, Peng Y, Wang D, Nebigil CG, Désaubry L

Eur J Med Chem. 2022 08 4;242:114635

Fluorizoline Blocks the Interaction between Prohibitin-2 and γ-Glutamylcyclotransferase and Induces p21Waf1/Cip1 Expression in MCF7 Breast Cancer Cells

Takagi H, Moyama C, Taniguchi K, Ando K, Matsuda R, Ando S, Ii H, Kageyama S, Kawauchi A, Chouha N, Désaubry L, Nakata S

Mol Pharmacol. 2021 Dec 3;:

Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells.

Tortelli TC, Tamura RE, de Souza Junqueira M, da Silva Mororó J, Bustos SO, Natalino RJM, Russell S, Désaubry L, Strauss BE, Chammas R

Aging (Albany NY). 2021 Sep 16;13(undefined):

Prohibitin Inactivation in Adipocytes Results in Reduced Lipid Metabolism and Adaptive Thermogenesis Impairment.

Gao Z, Daquinag AC, Fussell C, Djehal A, Désaubry L, Kolonin MG

Diabetes. 2021 Jul 13;:

Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies.

Hsu PY, Mammadova A, Benkirane-Jessel N, Désaubry L, Nebigil CG

Front Cardiovasc Med. 2021 ;8:694711

Prohibitin, STAT3 and SH2D4A physically and functionally interact in tumor cell mitochondria.

Ploeger C, Huth T, Sugiyanto RN, Pusch S, Goeppert B, Singer S, Tabti R, Hausser I, Schirmacher P, Désaubry L, Roessler S

Cell Death Dis. 2020 Nov 30;11(11):1023

Development of prohibitin ligands against osteoporosis.

Tabti R, Lamoureux F, Charrier C, Ory B, Heymann D, Bentouhami E, Désaubry L

Eur J Med Chem. 2020 Oct 23;:112961

Evolutionarily conserved SFPH proteins as therapeutic targets for a myriad of diseases.

Wang D, Tabti R, Elderwish S, Djehal A, Chouha N, Pinot F, Yu P, Nebigil CG, Désaubry L

Bioorg Med Chem Lett. 2020 Oct 6;:127600

Prokineticin signaling in heart-brain developmental axis: Therapeutic options for heart and brain injuries.

Désaubry L, Kanthasam AG, Nebigi CG

Pharmacol. Res.. 2020 Sep 13;:105190

Flavagline synthetic derivative induces senescence in glioblastoma cancer cells without being toxic to healthy astrocytes.

Harmouch E, Seitlinger J, Chaddad H, Ubeaud-Sequier G, Barths J, Saidu S, Désaubry L, Grandemange S, Massfelder T, Fuhrmann G, Fioretti F, Dontenwill M, Benkirane-Jessel N, Idoux-Gillet Y

Sci Rep. 2020 Aug 13;10(1):13750

Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.

Nebigil CG, Moog C, Vagner S, Benkirane-Jessel N, Smith DR, Désaubry L

Eur J Med Chem. 2020 Jul 15;203:112653

The synthetic small molecule FL3 combats intestinal tumorigenesis via Axin1-mediated inhibition of Wnt/beta-catenin signaling.

Jackson DN, Alula KM, Delgado-Deida Y, Tabti R, Turner K, Wang X, Venuprasad K, Souza RF, Désaubry L, Theiss AL

Cancer Res.. 2020 Jul 14;:

A subset of flavaglines inhibits KRAS nanoclustering and activation.

Yurugi H, Zhuang Y, Siddiqui FA, Liang H, Rosigkeit S, Zeng Y, Abou-Hamdan H, Bockamp E, Zhou Y, Abankwa D, Zhao W, Désaubry L, Rajalingam K

J. Cell. Sci.. 2020 May 22;:

The prohibitin-binding compound fluorizoline affects multiple components of the translational machinery and inhibits protein synthesis.

Jin X, Xie J, Zabolocki M, Wang X, Jiang T, Wang D, Desaubry L, Bardy C, Proud CG

J. Biol. Chem.. 2020 May 19;:

Recent advances in the synthesis of 2,3-dihydropyrroles.

Wang D, Fan Y, Yu P, Désaubry L

Chem. Commun. (Camb.). 2020 May 13;:

A One-Pot Selective Saturation and Functionalization of Heteroaromatics Leading to Dihydropyridines and Dihydroquinolines.

Wang D, Jiang Y, Dong L, Li G, Sun B, Desaubry L, Yu P

J. Org. Chem.. 2020 Mar 10;:

Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases.

Wang D, Tabti R, Elderwish S, Abou-Hamdan H, Djehal A, Yu P, Yurugi H, Rajalingam K, Nebigil CG, Désaubry L

Cell. Mol. Life Sci.. 2020 Feb 15;:

A subset of flavaglines inhibits KRAS nanoclustering and activation.

Yurugi H, Zhuang Y, Siddiqui FA, Liang H, Rosigkeit S, Zeng Y, Abou-Hamdan H, Bockamp E, Zhou Y, Abankwa D, Zhao W, Désaubry L, Rajalingam K

J Cell Sci. 2020 Jan 1;:

An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.

Shen S, Faouzi S, Bastide A, Martineau S, Malka-Mahieu H, Fu Y, Sun X, Mateus C, Routier E, Roy S, Desaubry L, André F, Eggermont A, David A, Scoazec JY, Vagner S, Robert C

Nat Commun. 2019 Dec 16;10(1):5713

Discovery of 3,3'-pyrrolidinyl-spirooxindoles as cardioprotectant prohibitin ligands.

Elderwish S, Audebrand A, Nebigil CG, Désaubry L

Eur J Med Chem. 2019 Nov 9;:111859

Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.

Bentayeb H, Aitamer M, Petit B, Dubanet L, Elderwish S, Désaubry L, de Gramont A, Raymond E, Olivrie A, Abraham J, Jauberteau MO, Troutaud D

J. Exp. Clin. Cancer Res.. 2019 Nov 4;38(1):450

Prokineticin Receptor-1 Signaling Inhibits Dose- and Time-Dependent Anthracycline-Induced Cardiovascular Toxicity Via Myocardial and Vascular Protection.

Gasser A, Chen YW, Audebrand A, Daglayan A, Charavin M, Escoubet B, Karpov P, Tetko I, Chan MWY, Cardinale D, Désaubry L, Nebigil CG

JACC CardioOncol. 2019 Sep;1(1):84-102

PHB2 (prohibitin 2) promotes PINK1-PRKN/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis.

Yan C, Gong L, Chen L, Xu M, Abou-Hamdan H, Tang M, Désaubry L, Song Z

Autophagy. 2019 Jun 10;:

The synthetic flavagline FL3 spares normal human skin cells from its cytotoxic effect via an activation of Bad.

Emhemmed F, Azouaou SA, Hassan S, Lefevbre R, Désaubry L, Muller CD, Fuhrmann G

Toxicol In Vitro. 2019 Apr 24;:

Stereoselective Four-Component Synthesis of Functionalized 2,3-Dihydro-4-Nitropyrroles.

Wang D, Ma X, Dong L, Feng H, Yu P, Désaubry L

Front Chem. 2019 ;7:810

Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments.

Audebrand A, Désaubry L, Nebigil CG

Front Cardiovasc Med. 2019 ;6:194

Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.

Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C, Agoussi S, Estrada C, Adam J, Libenciuc C, Routier E, Roy S, Désaubry L, Eggermont AM, Sonenberg N, Scoazec JY, Eychène A, Vagner S, Robert C

Nat. Med.. 2018 Oct 29;:

Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes.

Neal M, Luo J, Harischandra DS, Gordon R, Sarkar S, Jin H, Anantharam V, Désaubry L, Kanthasamy A, Kanthasamy A

Glia. 2018 Sep 12;:

The role of GPCR signaling in cardiac Epithelial to Mesenchymal Transformation (EMT).

Nebigil CG, Désaubry L

Trends Cardiovasc. Med.. 2018 Aug 22;:

Emergence of cardio-oncology.

Nebigil CG, Désaubry L

Ann Pharm Fr. 2018 Jul 31;:

Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells.

Djehal A, Krayem M, Najem A, Hammoud H, Cresteil T, Nebigil CG, Wang D, Yu P, Bentouhami E, Ghanem GE, Désaubry L

Eur J Med Chem. 2018 Jun 23;155:880-888

The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells but fails to prevent leukemia development in a murine model.

Wierz M, Pierson S, Chouha N, Désaubry L, François JH, Berchem G, Paggetti J, Moussay E

Haematologica. 2018 Apr;103(4):e154-e157

The mTOR-S6 kinase pathway promotes stress granule assembly.

Sfakianos AP, Mellor LE, Pang YF, Kritsiligkou P, Needs H, Abou-Hamdan H, Désaubry L, Poulin GB, Ashe MP, Whitmarsh AJ

Cell Death Differ.. 2018 Mar 9;:

Scalable 9-Step Synthesis of the Splicing Modulator NVS-SM2.

Abou-Hamdan H, Désaubry L

J. Org. Chem.. 2018 Mar 2;83(5):2954-2958

Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.

Yuan G, Chen X, Liu Z, Wei W, Shu Q, Abou-Hamdan H, Jiang L, Li X, Chen R, Désaubry L, Zhou F, Xie D

J. Exp. Clin. Cancer Res.. 2018 Feb 7;37(1):21

CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts.

Tabet R, Schaeffer L, Freyermuth F, Jambeau M, Workman M, Lee CZ, Lin CC, Jiang J, Jansen-West K, Abou-Hamdan H, Désaubry L, Gendron T, Petrucelli L, Martin F, Lagier-Tourenne C

Nat Commun. 2018 Jan 11;9(1):152

Updates in Anthracycline-Mediated Cardiotoxicity.

Nebigil CG, Désaubry L

Front Pharmacol. 2018 ;9:1262

Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.

Yurugi H, Marini F, Weber C, David K, Zhao Q, Binder H, Désaubry L, Rajalingam K

Oncogene. 2017 Apr;:

Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.

Malka-Mahieu H, Newman M, Désaubry L, Robert C, Vagner S

Clin. Cancer Res.. 2017 Jan;23(1):21-25

Pro-differentiating effects of a synthetic flavagline on human teratocarcinomal cancer stem-like cells.

Emhemmed F, Ali Azouaou S, Zhao Q, Appert-Collin A, Bennasroune A, Schini-Kerth VB, Muller CD, Désaubry L, Fuhrmann G

Cell Biol. Toxicol.. 2016 Dec;:

STAT1 Promotes KRAS Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4A.

Wang S, Darini C, Désaubry L, Koromilas AE

Mol. Cancer Ther.. 2016 Dec;15(12):3055-3063

Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.

Malka-Mahieu H, Girault I, Rubington M, Leriche M, Welsch C, Kamsu-Kom N, Zhao Q, Desaubry L, Vagner S, Robert C

Cell Cycle. 2016 Sep;15(18):2405-9

Flavaglines Ameliorate Experimental Colitis and Protect Against Intestinal Epithelial Cell Apoptosis and Mitochondrial Dysfunction.

Han J, Zhao Q, Basmadjian C, Désaubry L, Theiss AL

Inflamm. Bowel Dis.. 2016 Jan;22(1):55-67

Revision of the Synthesis and Pharmacological Activity of a Reported Translation Inhibitor.

Basmadjian C, Malka-Mahieu H, Desaubry L

Anticancer Agents Med Chem. 2015 Jun 1.

P5.02Development of Novel Anticancer Agents that Target Prohibitins and the Translation Initiation Factor eIF4A.

Desaubry L, Zhao Q, Basmadjian C, Thuaud F, Ribeiro N, Nebigil C, Eggermont A, Robert C, Vagner S

Ann Oncol. 2015 Mar;26 Suppl 2:ii25-ii26

Assessment of flavaglines as potential chikungunya virus entry inhibitors.

Wintachai P, Thuaud F, Basmadjian C, Roytrakul S, Ubol S, Desaubry L, Smith DR

Microbiol Immunol. 2015 Feb 3

Discovery and cardioprotective effects of the first non-Peptide agonists of the g protein-coupled prokineticin receptor-1.

Gasser A, Brogi S, Urayama K, Nishi T, Kurose H, Tafi A, Ribeiro N, Desaubry L, Nebigil CG

PLoS One. 2015 Apr 1;10(4):e0121027

FL3, a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity.

Qureshi R, Yildirim O, Gasser A, Basmadjian C, Zhao Q, Wilmet JP, Desaubry L, Nebigil CG

PLoS One. 2015 Nov 4;10(11):e0141826

Flavaglines Stimulate Transient Receptor Potential Melastatin Type 6 (TRPM6) Channel Activity.

Blanchard MG, de Baaij JH, Verkaart SA, Lameris AL, Basmadjian C, Zhao Q, Desaubry L, Bindels RJ, Hoenderop JG

PLoS One. 2015 Mar 16;10(3):e0119028

Novel carbocationic rearrangements of 1-styrylpropargyl alcohols.

Basmadjian C, Zhang F, Desaubry L

Beilstein J Org Chem. 2015 Jun 15;11:1017-22

Search for the Most 'primitive' Membranes and Their Reinforcers: A Review of the Polyprenyl Phosphates Theory.

Nakatani Y, Ribeiro N, Streiff S, Gotoh M, Pozzi G, Desaubry L, Milon A

Orig Life Evol Biosph. 2014 Oct 30.

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Desaubry L, Robert C, Vagner S

Nature. 2014 Sep 4;513(7516):105-9

Benzofuran derivatives as anticancer inhibitors of mTOR signaling.

Salome C, Ribeiro N, Chavagnan T, Thuaud F, Serova M, de Gramont A, Faivre S, Raymond E, Desaubry L

Eur J Med Chem. 2014 Jun 23;81:181-91

Selective anticancer effects of a synthetic flavagline on human Oct4-expressing cancer stem-like cells via a p38 MAPK-dependent caspase-3-dependent pathway.

Emhemmed F, Ali Azouaou S, Thuaud F, Schini-Kerth V, Desaubry L, Muller CD, Fuhrmann G

Biochem Pharmacol. 2014 May 15;89(2):185-96

Benzofuran derivatives as a novel class of inhibitors of mTOR signaling.

Salome C, Narbonne V, Ribeiro N, Thuaud F, Serova M, de Gramont A, Faivre S, Raymond E, Desaubry L

Eur J Med Chem. 2014 Mar 3;74:41-9

Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A.

Basmadjian C, Thuaud F, Ribeiro N, Desaubry L

Future Med Chem. 2013 Dec;5(18):2185-97

Prohibitin ligands in cell death and survival: mode of action and therapeutic potential.

Thuaud F, Ribeiro N, Nebigil CG, Desaubry L

Chem Biol. 2013 Mar 21;20(3):316-31

N-[3a-(4-Bromo-phen-yl)-8b-hy-droxy-6,8-dimeth-oxy-3-phenyl-2,3,3a,8b-tetra-hydro -1H-cyclo-penta-[b]benzofuran-1-yl]formamide monohydrate.

Aubert E, Thuaud F, Ribeiro N, Desaubry L, Espinosa E

Acta Crystallogr Sect E Struct Rep Online. 2013 Jan 1;69(Pt 1):o52-3

Flavaglines as potent anticancer and cytoprotective agents.

Ribeiro N, Thuaud F, Bernard Y, Gaiddon C, Cresteil T, Hild A, Hirsch EC, Michel PP, Nebigil CG, Desaubry L

J Med Chem. 2012 Nov 26;55(22):10064-73

Search for the most primitive membranes: some remaining problems.

Nakatani Y, Ribeiro N, Streiff S, Desaubry L, Ourisson G

Orig Life Evol Biosph. 2012 Oct;42(5):497-501

Recent advances in the biology and chemistry of the flavaglines.

Ribeiro N, Thuaud F, Nebigil C, Desaubry L

Bioorg Med Chem. 2012 Mar 15;20(6):1857-64

Cytochromes P450 CYP94C1 and CYP94B3 catalyze two successive oxidation steps of plant hormone Jasmonoyl-isoleucine for catabolic turnover.

Heitz T, Widemann E, Lugan R, Miesch L, Ullmann P, Desaubry L, Holder E, Grausem B, Kandel S, Miesch M, Werck-Reichhart D, Pinot F

J Biol Chem. 2012 Feb 24;287(9):6296-306

Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27.

Bernard Y, Ribeiro N, Thuaud F, Turkeri G, Dirr R, Boulberdaa M, Nebigil CG, Desaubry L

PLoS One. 2011;6(10):e25302

Novel flavaglines displaying improved cytotoxicity.

Thuaud F, Ribeiro N, Gaiddon C, Cresteil T, Desaubry L

J Med Chem. 2011 Jan 13;54(1):411-5

Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.

Polier G, Ding J, Konkimalla BV, Eick D, Ribeiro N, Kohler R, Giaisi M, Efferth T, Desaubry L, Krammer PH, Li-Weber M

Cell Death Dis. 2011 Jul 21;2:e182

Unprecedented Elimination of Conjugated Phenylthioether Groups by Low-Valent Titanocene.

Ribeiro N, Fetzer L, Streiff S, Desaubry L

Synlett. 2010 Dec;19:2928-30.

Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.

Thuaud F, Bernard Y, Turkeri G, Dirr R, Aubert G, Cresteil T, Baguet A, Tomasetto C, Svitkin Y, Sonenberg N, Nebigil CG, Desaubry L

J Med Chem. 2009 Aug 27;52(16):5176-87.

Tandem Diels-Alder-manganese dioxide mediated oxidation reaction. A short route to marcanines

Mekideche S, Desaubry L

Tetrahedron Lett. 2008 Sep 1;49(36):5268-70

Regioselectivity of fluorine substitution by alkoxides on unsymmetrical difluoroarenes

Dirr R, Anthaume C, Desaubry L

Tetrahedron Lett. 2008 Jul 28;49(31):4588-90

Synthesis and biological evaluation of PEG-tirofiban conjugates.

Desaubry L, Riche S, Laeuffer P, Cazenave JP

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2028-31

Synthesis of 3-O-methylviridicatin analogues with improved anti-TNF-alpha properties.

Ribeiro N, Tabaka H, Peluso J, Fetzer L, Nebigil C, Dumont S, Muller CD, Desaubry L

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5523-4

Reinforcing effect of bi- and tri-cyclopolyprenols on 'primitive' membranes made of polyprenyl phosphates

Ribeiro N, Streiff S, Heissler D, Elhabiri M, Albrecht-Gary AM, Atsumi M, Gotoh M, Desaubry L, Nakatani Y, Ourisson G

Tetrahedron. 2007 Apr 16;63(16):3395-407.

Looking forward: a glance into the future of organic chemistry.

Compain P, Desvergnes V, Ollivier C, Robert F, Suzenet F, Barboiu M, Belmont P, Bleriot Y, Bolze F, Bouquillon S, Bourguet E, Braida B, Constantieux T, Desaubry L, Dupont D, Stephane G, Jerome F, Legoupy S, Marat X, Marie M, Moitessier N, Papot S, Peri F, Petit M, Py S, Schulz E, Isabelle TO, Vauzeilles B, Philippe V, Vergnes L, Vidal S, Wilmouth S

New J Chem. 2006 Jun;30(6):823-31.

Future alchemy: account of the ESYOP experiment..

Compain P, Desvergnes V, Ollivier C, Robert F, Suzenet F, Barboiu M, Belmont P, Bleriot Y, Bolze F, Bouquillon S, Bourguet E, Braida B, Constantieux T, Desaubry L, Dupont D, Gastaldi S, Jerome F, Legoupy S, Marat X, Migaud M, Moitessier N, Papot S, Peri F, Petit M, Py S, Schulz E, Tranoy-Opalinski I, Vauzeilles B, Vayron P, Vergnes L, Vidal S, Wilmouth S

C R Chim. 2006 Jan;9(1):127-40.

Fiche personne Projets Publications

Retrouvez aussi

Personnes

Equipes

Plateformes

Unités de recherche, établissements

Projets de recherche

Publications scientifiques